The drug Zofran was permitted to be used in the United States in 1991. The intended and authorized use of the drug was to mitigate nausea suffered by cancer patients going through chemo and radiation therapy and those who have had a medical procedure. Unfortunately, Zofran started being given to pregnant women who were suffering from Hyperemesis gravidarum (HG), which is persistent nausea and vomiting in pregnant women, in some cases leading to them being hospitalized.
Zofran was never thoroughly tested by GlaxoSmithKline (GSK) for use in pregnant women and subsequently babies were born with birth defects. Clinical studies have been carried out and linked Zofran to specific defects such as cleft palate and congenital heart defects. Zofran has never been approved by the FDA for use in pregnant women. As birth defects have been proved in association with Zofran, lawsuits have since been filed in relation to Zorfan causing defects in mothers who took the drug in the first 12 weeks of pregnancy.
South Dakota: Infant Birth Defects Data
A one in 33 chance of a baby being born with a birth defect is the recorded national data. The reasons for an infant being born with a birth abnormality are not all the same and can vary from genetic issues to medical negligence. In order to know the infant birth defects in South Dakota a record of the states population was used. South Dakota’s latest population estimate is 853,157 as recorded in 2014.
Our Zofran team weighed South Dakota State in order to work out the probable cases related to Zofran birth defects based on the information available from previously performed clinical studies that correlated specific types of defects to Zofran consumption, as well as the birth rates and population figure in the state. The resulting figure was 450 infant birth defects that were affected by Zofran.
The populations of the five most inhabited cities in South Dakota are as follows:
- Sioux Falls- 153,888 population
- Rapid City- 67,956 population
- Aberdeen- 26,091 population
- Brookings- 22,056 population
- Watertown- 21,482 population
Probable Stats For Orofacial Cleft & Hole In The Heart Defects In South Dakota
Making use of the South Dakota population of 853,175 we have calculated a probable 80 infant birth irregularities in the form of orofacial cleft and 370 births with hole in the heart defects. For the five major cities in South Dakota the probable stats are as follows:
- Sioux Falls- 122 infant birth irregularities with a probable 14 orofacial cleft, and 108 hole in the heart defects
- Rapid City- 82 infant birth irregularities with a probable 7 orofacial cleft, and 75 hole in the heart defects
- Aberdeen- 62 infant birth irregularities with a probable 2 orofacial cleft, and 60 hole in the heart defects
- Brookings- 60 infant birth irregularities with a probable 2 orofacial cleft, and 58 hole in the heart defects
- Watertown- 60 infant birth irregularities with a probable 6 orofcaial cleft, and 54 hole in the heart defects
What Are The Documented Infant Birth Irregularities?
Filed lawsuits and undertaken studies by the medical community have all correlated the effects of Zofran on fetal development. One of those studies by CDC and Sloan Epidemiology relayed that Zofran increased the chances of a baby being with a cleft palate, in cases where a mother took Zofran in her first 12 weeks of pregnancy, by 2.37 times. Read more about this study here. Documented infant birth irregularities have included congenital heart defects and cleft palate. Despite this medical research, GSK refuses to acknowledge that Zofran causes infant birth irregularities.
In already filed lawsuits, litigants have stated that Zofran caused the following defects:
- Renal Malformations
- Webbed Toes
- Club Foot
- Bicuspid aortic stenosis
- Heart murmurs
- Facial Dysmorphia
- Cleft Palate
Parents Seeking Justice In South Dakota
Parents from South Dakota are seeking justice by visiting ZofranLegal.com as they suspect Zofran was the cause of their child being born with a birth abnormality. ZofranLegal.com is a website financed by various law firms from different parts of the country as a resource for up to date information about the Zofran litigation. Although our advocates do not have the authority to practice law in the state of South Dakota, we are authorized to practice law in and have offices in Delaware. Delaware is the place where GSK, the makers of Zofran have their headquarters. This means we are able to represent your case in a litigation that is filed in Delaware.
In terms of filing your Zofran lawsuit, we have several filing options. You could file your case in Delaware, the state where GSK has its headquarters, or you can file at a location that is more suited to you. Alternatively, a lawsuit can be filed in South Dakota using one of our trusted legal counsel who will take care of your case.
Many questions are very possible at this time and we encourage you to get in touch with us and we can discuss your case specifics. We are available to speak to you at any time of the day or night. Meet our Zofran team here as well.
Orofacial Cleft & Hole In The Heart Defects Information In South Dakota
Medicinet Rapid City:
Baby’s First Test: